Novel JAK2 Inhibitor Piperadine Aniline Derivatives of Ruxolitinib to Treat Myelofibrosis
FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICE
Contact
Haskell Adler PhD MBA CLP
Senior Licensing Manager
Haskell.Adler@Moffitt.org
(813) 745-6596